Drug profile · INN
nirsevimab-alip
BEYFORTUS
nirsevimab-alip (BEYFORTUS) is a fusion glycoprotein f0 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — nirsevimab-alip
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nirsevimab-alip (BEYFORTUS) is a fusion glycoprotein f0 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Fusion glycoprotein F0 inhibitor
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nirsevimab-alip?
nirsevimab-alip (BEYFORTUS) is a fusion glycoprotein f0 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for nirsevimab-alip?
BEYFORTUS is a marketed brand name for nirsevimab-alip. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nirsevimab-alip?
nirsevimab-alip has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.